We represented AbbVie in a series of eight applications under the PMNOC Regulations relating to AbbVie’s blockbuster drug HUMIRA.  The cases related to four different patents and were among the first in Canada relating to a subsequent entry biologic (biosimilar) drug. These cases were settled during the cross-examination phase as part of a global settlement between AbbVie and Samsung Bioepis.